Pfizer Inc. (NYSE:PFE) Holdings Decreased by AdvisorNet Financial Inc

AdvisorNet Financial Inc trimmed its position in Pfizer Inc. (NYSE:PFE) by 2.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 56,832 shares of the biopharmaceutical company’s stock after selling 1,390 shares during the quarter. AdvisorNet Financial Inc’s holdings in Pfizer were worth $1,577,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. GoalVest Advisory LLC boosted its position in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the period. Creekmur Asset Management LLC acquired a new position in Pfizer during the 4th quarter valued at approximately $32,000. VisionPoint Advisory Group LLC boosted its position in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the period. Tennessee Valley Asset Management Partners acquired a new position in Pfizer during the 4th quarter valued at approximately $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new position in Pfizer during the 4th quarter valued at approximately $37,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. Morgan Stanley boosted their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, June 17th. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $35.86.

Pfizer Stock Up 2.2 %

Shares of Pfizer stock opened at $28.36 on Tuesday. The stock’s fifty day moving average is $27.72 and its 200-day moving average is $27.70. The firm has a market capitalization of $160.68 billion, a PE ratio of -472.50, a price-to-earnings-growth ratio of 1.09 and a beta of 0.70. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.80.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. Pfizer’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.23 earnings per share. Equities analysts anticipate that Pfizer Inc. will post 2.37 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.92%. The ex-dividend date was Thursday, May 9th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.